一次情報の記録
この業績リリースは、計画されているsBLAを裏付ける血液透析アクセスにおける肯定的な第3相V007およびV012の結果を要約しています。Humacyteは、透析アクセスにおけるATEVの補足生物製剤ライセンス申請(sBLA)が2026年11月にFDAに提出する予定通りであると述べています。
EX-99.1 2 huma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption – Commercial adoption of Symvess ® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2 nd quarter. – Symvess commercial momentum continued into the fourth quarter, with October 2026 sales totaling $0.8 million. – Supplemental Biologics License Application (sBLA) for the ATEV in dialysis access on track for filing with the Food and Drug Administration (FDA) in November 2026. – Company initiates first-in-human clinical Phase 2a study of CTEV for CABG. – Conference call today at 8:00 am ET. DURHAM, N.C., November 10, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commerc